Anbio Biotechnology (NNNN) Cash & Equivalents (2023 - 2025)

Anbio Biotechnology has reported Cash & Equivalents for 3 years, with the latest figure at $7.8 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 33.96% year-over-year to $7.8 million in Q4 2025; TTM through Dec 2025 was $7.8 million, a 33.96% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 33.96% from the prior year.
• Cash & Equivalents was $7.8 million for Q4 2025 at Anbio Biotechnology, up from $5.3 million in the prior quarter.
• The five-year high for Cash & Equivalents was $11.8 million in Q4 2024, with the low at $5.3 million in Q2 2025.
• Average Cash & Equivalents over 3 years is $8.6 million, with a median of $8.7 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents climbed 21.4% in 2024, then slumped 33.96% in 2025.
• Over 3 years, Cash & Equivalents stood at $9.7 million in 2023, then climbed by 21.4% to $11.8 million in 2024, then plunged by 33.96% to $7.8 million in 2025.
• The last three Cash & Equivalents figures came in at $7.8 million (Q4 2025), $5.3 million (Q2 2025), and $11.8 million (Q4 2024), per Business Quant data.